Nimodipine (Nimotop) in cognitive disturbances


Cite item

Full Text

Abstract

This article discusses mechanisms of action and clinical effect of calcium channel blocker nimodipine. It is emphasized that to date this drug is used for subarachnoid hemorrhage, ischemic stroke and dementia of different genesis (vascular and primary degenerative). This drug has not only symptomatic action, improving the cognitive and behavioral function in patients with dementia, but also impact on the mechanisms of development of cognitive disorders. Side effects during therapy are rare, and it seems particularly important for of elderly and senile patients.

About the authors

I V Damulin

I V Damulin

References

  1. Андреев Н.А., Моисеев В.С. Антагонисты кальция в клинической медицине. М., 1995. 161 с.
  2. Козловский В.Л. Влияние блокаторов кальциевых каналов на эффективность галоперидола и фенамина у мышей и крыс // Экспериментальная и клиническая фармакология. 1996. Т. 59. С. 12-15.
  3. Стаховская Л.В., Чекнева Н.С. Нимотоп С в лечении цереброваскулярной патологии. Методические рекомендации / Под ред. Л.Г. Ерохиной. М., 1995. 20 с.
  4. Яхно Н.Н. Когнитивные расстройства в неврологической клинике // Неврологический журнал. 2006. Т. 11. Прилож. 1. С. 4-12.
  5. Avery RB, Johnston D. Multiple channel types contribute to the low-voltage-activated calcium current in hippocampal CA3 pyramidal neurons. J Neurosci 1996;16:5567-82.
  6. Ban TA, Morey L, Aguglia E, et al. Nimodipine in the treatment of old age dementias. Prog Neuro-Psychopharmacol Biol Psychiatr 1990;14:525-51.
  7. Besson JAO, Palin AN, Ebmeyer KP, et al. Calcium antagonists and multi-infarct dementia: a trial involving sequential NMR and psychometric assessment. Intern J Geriatr Psychiatry 1988;3:99-105.
  8. Campbell LW, Hao SY, Thibault O, et al. Aging changes in voltage-gated calcium currents in hippocampal CA1 neurons. J Neurosci 1996;16:6286-95.
  9. De Riu PL, Demontis MP, Anania V, et al. Brain electrobiogenesis protection induced by nimodipine and MK-801 during acute hypoxia in hypertensive rats. Pharmacol Res 1995;31:169-73.
  10. Eicher H, Hilgert D, Zeeh J, et al. Pharmacokinetics of nimodipine in multimorbid elderly patients with chronic brain failure. Arch Gerontol Geriatr 1992;14:309-19.
  11. Ercan M, Inci S, Kilinc K, et al. Nimodipine attenuates lipid peroxidation during the acute phase of head trauma in rats. Neurosurg Rev 2001;24:127-30.
  12. Erkinjuntti T. Subcortical vascular dementia - diagnostic problems. In: 7th IPA Congress. Sydney, Australia, 1995:45.
  13. Ferszt R, Kanowski S. Nimodipine in the treatment of dementia. Drugs Today 1998;34:767-76.
  14. Frisoni GB, Galluzzi S, Bresciani L, et al. Mild cognitive impairment with subcortical vascular features. Clinical characteristics and outcome. J Neurol 2002;249:1423-32.
  15. Grobe-Einsler R. Clinical aspects of nimodipine. Neurobiol Aging 1993;13:S39-45.
  16. Hauerberg J, Rasmussen G, Juhler M, et al. The effect of nimodipine on autoregulation of cerebral blood flow after subarachnoid haemorrhage in rat. Acta Neurochir (Wien) 1995;132:98-103.
  17. Herz RC, De Wildt DJ, Versteeg DH. The effects of gamma 2-melanocyte-stimulating hormone and nimodipine on cortical blood flow and infarction volume in two rat models of middle cerebral artery occlusion. Eur J Pharmacol 1996;306:113-21.
  18. Kabuto H, Yokoi I, Mori A. Neurochemical changes related to ageing in the senescence-accelerated mouse brain and the effect of chronic administration of nimodipine. Mech Ageing Dev 1995;80:1-9.
  19. Kanowski S, Fischhov P, Hiersemenzel R, et al. Therapeutic efficacy of nootropic drugs - a discussion of clinical phase III studies with nimodipine as a model. In: Diagnosis and treatment of senile dementia. M. Bergener, B. Reisberg (Eds.). Berlin etc.: Springer-Verlag 1989:339-49.
  20. Kazda S, Gartoff B, Krause HP, et al. Cerebrovascular effects of calcium antagonistic dihydropyidine deriviative nimodipine in animal experiments. Drugs Res 1982;32:331-38.
  21. Korenkov AI, Pahnke J, Frei K, et al. Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev 2000;23:145-50.
  22. Knopman DS. Treatment of mild cognitive impairment and prospects for prevention of Alzheimer's disease. In: Mild Cognitive Impairment: Aging to Alzheimer's Disease. Ed. by R.C.Petersen. Oxford: Oxford University Press 2003:243-58.
  23. Landfield PW. Calcium homeostasis in brain ageing and Alzheimer's disease. In: Diagnosis and Treatment of Senile Dementia. Ed by. M.Bergener, B.Reisberg. Berlin: Springer Verlag 1989:276-87.
  24. Levere TE, Walker A. Old age and cognition enhancement of recent memory in aged rats by the calcium channel blocker nimodipine. Neurobiol Aging 1991;13:63-66.
  25. Lopez-Arrieta J. Nimodipine. /In: Evidence-based Dementia Practice. Ed. by N.Qizilbash et al. Oxford: Blackwell Science 2002:537-40.
  26. Luiten PG, Douma BR, Van der Zee EA, et al. Neuroprotection against NMDA induced cell death in rat nucleus basalis by Ca2+ antagonist nimodipine, influence of aging and developmental drug treatment. Neurodegeneration 1995;4:307-14.
  27. Lustig HS, Ahern KB, Greenberg DA. Omega-agatoxin IVA and excitotoxicity in cortical neuronal cultures. Neurosci Lett 1996;213:142-44.
  28. Nomura M. Effect of nimodipine on brightness discrimination learning test in Wistar Kyoto and spontaneously hypertensive rats. Drugs Res 1988;38:1282-86.
  29. Noskovic P, Faberova V, Fabianova M. Effect of a combination of pentoxifylline and nimodipine on lipid peroxidation in postischemic rat brain. Mol Chem Neuropathol 1995;25:97-102.
  30. Pantoni L, Rossi R, Inzitari D, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 2000;175:124-34.
  31. Pantoni L, del Ser T, Soglian AG, et al. Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial. Stroke 2005;36:619-24.
  32. Sandin M, Jasmin S, Levere T. Aging and cognition. Facilitation of recent memory in aged nonhuman primates by nimodipine. Neurobiol Aging 1990;11:573-75.
  33. Scriabine A. Pharmacology overview: Nimodipine in CNS indications. In: Nimodipine: Pharmacological and clinical results in cerebral ischemia. A.Scriabine et al (Eds.). Berlin etc.: Springer-Verlag 1991:1-7.
  34. Sobrado M, Lopez MG, Carceller F, et al. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia. Neuroscience 2003;118:107-13.
  35. Stuiver BT, Douma BR, Bakker R, et al. In vivo protection against NMDA-induced neurodegeneration by MK-801 and nimodipine: combined therapy and temporal course of protection. Neurodegeneration 1996;5:153-59.
  36. Sze KH, Sim TC, Wong E, et al. Effect of nimodipine on memory after cerebral infarction. Acta Neurol Scand 1998;97:386-92.
  37. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine (Bay-e-9736) in the management of primary degenerative dementia. Biol Psychiatr 1990;27:1133-42.
  38. Tomassoni D, Lanari A, Silvestrelli G, et al. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypert 2008;30:744-66.
  39. Viveros MP, Martin S, Ormazabal M, et al. Effects of nimodipine and nifedipine upon behavior and regional brain monoamines in the rat. Psychopharmacology (Berl.) 1996;127:123-32.
  40. Yanpallewar SU, Hota D, Rai S, et al. Nimodipine attenuates biochemical, behavioral and histopathological alterations induced by acute transient and long-term bilateral common carotid occlusion in rats. Pharmacol Res 2004;49:143-50.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies